The Business Council of New York State is not supporting legislation that seeks to amend the pharmaceutical law governing the purchase of prescription drugs. Read More »
New safety and efficiency data included on labels after EAGLES clinical trial. Read More »
Cigna Corp. may receive additional price discounts from pharmaceutical companies should new cholesterol medications prove less effective than expected — a move marks a crucial step in a broader initiative to link the cost of medications to their efficacy. Read More »
Fourteen presentations will present results of avelumab treatments for seven different cancer types. Read More »
Pfizer will showcase its growing portfolio of innovative treatments for a variety of cancers. Read More »
Communication key to developing treatment goals and disease management plan. Read More »
Pfizer will acquire crisaborole, a treatment for eczema, in the deal. Read More »
The clinical trial will test bococizumab versus a placebo in reducing the risk of a major cardiovascular event. Read More »
CHANTIX/CHAMPIX compared to bupropion, nicotine patch and placebo; study finds significantly higher abstention rates. Read More »
Adding IBRANCE (palbociclib) to letrozole treatment for advanced or metastatic breast cancer improves progression-free survival rate. Read More »
The Phase III SIERRA clinical trial will test effectiveness of Iomab-B when used prior to bone marrow transplants. Read More »
Pfizer and IBM announced today a novel research partnership that will lead to the development of groundbreaking remote monitoring solutions focused on revolutionizing the care Parkinson’s patients receive. Read More »
The U.S. Food and Drug Administration (FDA) has approved Celltrion’s INFLECTRA (biosimilar infliximab) for all qualified indications of the reference product, Remicade (infliximab). Read More »
Pfizer has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has approved a new presentation of Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, absorbed]). Read More »
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Iomab-B, a radioimmunotherapeutic developed by Actinium Pharmaceuticals that is designed to aid patients with reverted and stubborn Acute Myeloid Leukemia (AML) so they can receive a Hematopoietic Stem Cell Transplant (HSCT). Read More »
Actinium Pharmaceuticals has announced that it has named Jennifer Liberi Director of Clinical Operations. Read More »
Pfizer and Bristol-Myers Squibb have released the 17 abstracts that the two companies will present at the American College of Cardiology’s 65th Annual Scientific Session (ACC.16) in Chicago on April 2-4. Read More »
Pfizer has announced that the European Medicines Agency (EMA) has accepted its Marketing Authorization Application (MAA) for XELJANZ (tofacitinib citrate) for review. Read More »
Pfizer has announced that it will be presenting new data based on the research of tofacitinib in ulcerative colitis (UC) and Crohn’s disease at the 11th Congress of ECCO, which is scheduled for March 16-19 in Amsterdam. Read More »
Pfizer today released its 2015 integrated annual review, which is an in-depth look at the company’s financial, social and environmental performance. Read More »
Alerts Sign-up
